We supply Linagliptin API

We're pleased to offer Linagliptin API, a important drug that's extensively used in the treatment of type 2 diabetes. Our Linagliptin is of the loftiest quality and chastity, and is manufactured in agreement with the strictest medicinal norms. This potent drug workshop by inhibiting an enzyme that breaks down incretin hormones, which in turn helps to regulate blood glucose situations. Whether you're creating a finished product or conducting exploration, our Linagliptin is the perfect choice for your requirements. communicate us moment to learn further about our Linagliptin API and to place your order.

What is Linagliptin?

Linagliptin is a pharmaceutical component that's used in the product of specifics for the treatment of type 2 diabetes. It belongs to the class of dipeptidyl peptidase- 4( DPP- 4) impediments, which work by blocking the action of the enzyme DPP- 4. This results in an increase of the situations of the hormone called incretin, which stimulates the product of insulin by the pancreas and reduces the product of glucose by the liver.

It offers several benefits compared to other DPP- 4 impediments. It has a longer partial- life, which means that it can be taken formerly a day rather of multiple times a day. It's metabolized primarily through fecal excretion, which makes it a good option for cases with renal impairment. It also has a lower threat of hypoglycemia, which is a common side effect of diabetes drug.

As a high- quality medicinal component, it is produced under strict manufacturing norms to insure chastity and energy. It's used by pharmaceutical companies to produce finished products similar as tablets, capsules, and injections. These products are specified by croakers to cases with type 2 diabetes and are an important part of managing the complaint.

it is just one of the numerous advances being made in the treatment of diabetes. With continued exploration and development, we hope to find new and better ways to help people with this complaint live healthier and further satisfying lives.

Basic Information

Product Name: Linagliptin

CAS: 668270-12-0

MF:C25H28N8O2

MW:472.54

EINECS:1308068-626-2

MDL No.:MFCD14635356

Structural formula:

Origin: China

Delivery Time: in stock

Application: Antidiabetic;Treat Diabetes

Technical Specification

Package: 1kg;5kg or according to your demands

Storage conditions: protected from light and moisture, sealed and dry

Transportation conditions: 2-8 ℃ transportation

Shelf Life:Powder: 2 years

Application:

Linagliptin API, developed by Boehringer Ingelheim, was approved by FDA on May 2, 2011 to ameliorate the control of blood sugar position in cases with type 2 diabetes by combining diet and exercise. it improves blood glucose control in cases by inhibiting dipeptidyl peptidase- 4( DPP- 4).

Medium of action

it is a DPP- IV asset, which is an intestinal insulinotropic hormone that binds to proteins and exists in numerous apkins, similar as the encounter edges of the order, liver, small intestine membrane, pancreatic conduit, lymphocytes, endothelial cells, etc. This enzyme can inactivate GLP- 1 by hydrolyzing the alternate alanine at the N- outstation of GLP- 1. thus, inhibiting this enzyme can increase the attention of GLP- 1, promote island cells to produce insulin, and reduce the attention of glucagon, therefore playing an anti diabetes part. Liragliptin inhibits DPP- IV by tightly binding to ligands receptors and contending with substrates for binding spots. It's a picky, competitive, and reversible DPP- IV asset.

Side effect

The most common side effects of Liragliptin include upper respiratory tract infections, nasal traffic or watery nose, sore throat, muscle pain, headache,etc., and its medium still needs farther exploration.

Biological activity

Linagliptin(BI-1356) is a largely effective and picky DPP- 4 asset with an IC50 of 1nM. The selectivity of DPP- 4 is further than 10000 times advanced than other dipeptidyl peptidases similar as DPP- 2, DPP- 8, and DPP9. it can spark glomerular autophagy in type 2 diabetes model. DPP4 mediates iron death in TP53 deficient CRC cells.

In vitro exploration

In vitro, Linagliptin exhibits effective inhibitory goods on DPP- 4 and has low affinity for hERG channels and M1 receptors( IC50295nM). In vitro, it acts as a competitive asset with a Ki of 1nM. Its selectivity towards DPP- 4 is 10000 times advanced than that of DPP- 8, DPP- 9, aminopeptidases N and P, prolyl oligopeptidase, trypsin, fibrinolytic enzyme, and thrombin, and 90 times advanced than that of fibroblast activation protein.

In vivo exploration

Linagliptin exhibits effective, patient, and effective inhibitory exertion against DPP- 4 in manly Wistar rats, beagle tykes , and rhesus monkeys. Oral administration at a cure of 1mg/ kg can achieve inhibition of over 70 on all species. 45 twinkles before the oral glucose forbearance test, it was orally administered to db/ db mice, which cure dependently reduced blood glucose oscillations from0.1 mg/ kg( 15 inhibition) to 1mg/ kg( 66 inhibition). By inhibiting DPP- 4 exertion, it reduces the expression ofpro-inflammatory labels oxygenase- 2 and macrophage seditious protein- 2, and enhances the conformation of myofibroblasts during crack mending in ob/ ob mice.

Why Choose Xi'an Yihui?

Customer feedback

Xi'an Yihui certificates

Xi'an Yihui Factory & Warehouse

Contact Xi'an Yihui

In summary, Xi'an Yihui company as a professional Linagliptin API manufacturer has strong technical strength and advanced production equipment and is committed to providing customers with high-quality, efficient and reliable drug raw materials. if you need it, pls feel free to contact us any time. we will reply you ASAP.

Our contact information:

E-mail: sales@yihuipharm.com
Tel: 0086-29-89695240
WeChat or WhatsApp: 0086-17792415937